Request for Covid-19 Impact Assessment of this Report
ECMO is designed to provide temporary support when all other forms of conventional life support fail, and is not a cure for the underlying cause of cardiac or respiratory failure, but it does allow time for recuperation and/or response to conventional therapies. ECMO is broadly classified into two types- VA ECMO which is connected to both a vein and an artery and is used when there are problems with both the heart and lungs and VV ECMO which is connected to one or more veins, usually near the heart, and is used when the problem is only in the lungs.
Market Dynamics
Since the demand for the device arises mostly from open heart surgeries, for support during high-risk procedures in the cardiac catheterization lab,as a bridge to a heart assist device such as left ventricular assist device (LVAD), heart/lung transplants, for patients recovering from heart/lung failure and as a bridge for patients awaiting lung transplant, its Global demand is anticipated to increase considering the steady increase in the number of organ transplants performed throughout the world(made possible with advances in technology)with availability of matching organs being the only bottleneck for the surgery. With increased awareness about organ donation, and the number of smokers worldwide inching towards the 1 billion mark and the number of deaths as a result of direct tobacco use (which results in lung ailments) and rise in the number of people suffering from cardio-vascular(CVD) diseases- with them being the number one cause of death globally, around 17.7 million in 2015 alone, the market for ECMO has high growth prospects provided it efficiently addresses some of the associated risks from its usage like Small clots or air bubbles forming in the tubing, increased chance of stroke and infection at the sites where the tubes enter the body etc. amongst the others.
Market Segmentation:
The Global ECMO Devices market can be segmented on the basis of product into
--> VA ECMO
--> VV ECMO
--> AV ECMO
It can be segmented on the basis of application into
--> Cardiac
--> Respiratory
--> Extracorporeal cardiopulmonary resuscitation (ECPR)
Finally, it can also be segmented on the basis of region into
--> North America
--> Latin America
--> Europe
--> Africa
--> Middle-East
--> Asia Pacific
Regional/Geographic Analysis
Globally, North America is the largest player in the ECMO market owing to its advances in the field of science and technology, growing awareness about ECMO resulting in increased adoption of ECMO by hospitals supported by government initiatives. However, Asia-Pacific has bright growth potential considering its burgeoning middle class population, economic growth and a rapidly developing healthcare system.
Key Players
Some of the key players in the segment include:
--> Maquet Holding B.V. & Co. KG.
--> MedosMedizintechnik AG
--> Medtronic, Inc. (U.S.)
--> Microport Scientific Corporation
--> Nipro Medical Corporation
--> Sorin Group (Sorin S.P.A.)
--> Terumo Cardiovascular Systems Corporation
Report Contents:
> Market segments
> Market Drivers, Restraints and Opportunities
> Market Size & Forecast 2016 to 2022
> Supply & Demand Value Chain
> Market - Current Trends
> Competition & Major Companies
> Technology and R&D Status
> Porters Five Force Analysis
> Strategic and Critical Success Factor Analysis of Key Players
Regional Analysis:
> North America
>> US and Canada
> Latin America
>> Mexico, Brazil, Argentina and Rest of Latin America
> Western Europe
>> EU5 (Germany, France, Italy, Spain, U.K.)
>> Nordic Countries (Denmark, Finland, Norway, and Sweden)
>> Benelux (Belgium, The Netherlands, and Luxembourg)
>> Rest of Western Europe
> Eastern Europe
>> Russia
>> Poland
>> Rest of Eastern Europe
> Asia Pacific
>> China
>> India
>> Japan
>> Australia and New Zealand
>> Rest of Asia Pacific
> Middle East and Africa
>> GCC countries (Saudi Arabia, Oman, Qatar, Bahrain, UAE and Kuwait)
>> South Africa
>> North Africa
>> Rest of Middle East and Africa
This report is an elaborate aggregation of primary inputs from industry experts and participants across the supply chain. It provides details on market segmentation which is derived from several product mapping exercises, macroeconomic parameters and other qualitative and quantitative insights. The impact of all such factors is delivered across multiple market segments and geographies.
Report Highlights:
> Detailed Historical Overview (Market Origins, Product Launch Timeline, etc.)
> Consumer and Pricing Analysis
> Market dynamics of the industry
> Market Segmentation
> Estimated Market Sizing in terms of volume and value
> Recent trends in Market and impact
> Research Status and Technology Overview
> Extensive Industry Structure Coverage
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...